logo-loader

Ryanair shares fly lower on continuing fallout from move to cancel a number of flights for six weeks

Published: 09:17 18 Sep 2017 EDT

Ryanair planes
Ryanair is changing its holiday year, which currently runs from April to March, to run from January to December instead

Ryanair PLC (LON:RYA) saw its shares fly lower today on the continuing fallout from its move to cancel a number of flights for a period of six weeks in order to sort out holiday arrangements for its pilots.

The European Commission weighed in on the row today warning the Ireland and UK listed discount airline that it had to comply with EU rules on passenger rights, including possible reimbursement and compensation, over its plans to cancel between 40 and 50 flights per day until the end of October.

READ: Ryanair flies lower as it takes €50mln hit from new baggage policies

The Financial Times reported that an EC spokesman told a news conference: “Airlines operating in the EU need to respect the European rules ... Passengers whose flights are cancelled have a comprehensive set of rights.”

The newspaper said, he added: “We have to check if all this is respected by Ryanair. For instance, you are entitled to reimbursement if you are not warned two weeks in advance,” he said.

Ryanair is changing its holiday year, which currently runs from April to March, to run from January to December instead.

The airline has blamed a backlog of staff leave for the cancellations, which so far it has only given notice of up to this Wednesday, September 20 on its website - the vast number of which affect departures from London Stansted airport - with customer groups pressuring the firm to unveil a full list.

Meanwhile, Reuters reported today that Norwegian Air Shuttle has recruited more than 140 pilots from Ryanair in 2017, according to a spokesman for the Nordic budget rival.

In afternoon trading, Ryanair shares were 2.5%, or €0.43 lower in London at €16.71.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 3 minutes ago